Skip to main content

My account

Boston Scientific accounts are for healthcare professionals only.

Create an account to access online training and education on EDUCARE, manage your customer profile, and connect with customer support and service teams.

My Boston Scientific account

Access your online applications and manage your customer profile.

Manage my Boston Scientific account

Quick Links

Contact a representative
Online education and training
Order products online
Reimbursement resources
Return a product
Customer support

Call customer care

1 (888) 272-1001

Dark area showing tumor against blue background.

TheraSphere™ Y-90 Glass Microspheres

Combination therapies

Stimulate an immune response with TheraSphere1

TheraSphere is a well-tolerated and clinically proven locoregional treatment (LRT) to treat hepatocellular carcinoma (HCC) and has been shown to elicit an immune response.1,2

Y-90 shapes the microenvironment of HCC tumors by inducing tumor cell death and T cell recruitment and activation following therapy.1

Download TheraSphere & Systemics Brochure

Proven + well tolerated

TheraSphere targets the tumor while minimizing impact to surrounding healthy tissue. It safely delivers high-dose radiation directly to the tumor, yielding strong local tumor control. TheraSphere is well-tolerated with minimal side-effects, demonstrating long-term preservation of health-related quality of life (HRQoL).3

icon-liver.

In the LEGACY study, 0% of patients experienced radiation induced liver disease or failure.3

icon-stopwatch

Patients treated with TheraSphere were able to maintain adequate hepatic function for a measurable amount of time to allow for initiation of systemics.4

icon-circle-checkmark

TheraSphere preserves eligibility for future treatment options.5

See LEGACY study

The ROWAN Study

The ROWAN study is a global, open-label, multi-center, phase II, single-arm study to assess the efficacy of TheraSphere Y-90 Glass Microspheres followed by Durvalumab with Tremelimumab (STRIDE regimen) in patients with hepatocellular carcinoma. ROWAN will explore if there is a benefit of TheraSphere with immunotherapy to improve response for HCC patients.

Learn more about ROWAN
timeline of Rowan study stages from screening and enrollment to administration of therapies to follow-up.
Play button on laptop screen.

Pilot study on combination Pembrolizumab with TheraSphere Y-90 for HCC

OncLice Rapid Readout: William Harris, MD, presents an in-depth analysis of the HCRN GI15-225 pilot study, which explores the safety and efficacy of combining pembrolizumab with TheraSphere Y-90 radioembolization for non-metastatic, poor prognosis hepatocellular carcinoma (HCC).

Watch now

Collaboration to advance clinical research

With $30+M invested globally, Boston Scientific is actively supporting studies assessing the safety and efficacy of TheraSphere in combination with systemic therapies.

HCC stage focus

early, intermediate and advanced HCC stage focus.

Drug classification targets

drug classification targets PD-1, PD-L1, CTLA-4.

Boston Scientific is supporting studies across multiple stages and drug classification targets.

map pin icon.

Treatment center finder

Instantly locate treatment centers administering TheraSphere near you for your HCC patients.

Find a treatment center near you

References

  1. Chew 2018 Hepatology.
  2. Xing et al. Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization. BMC Cancer (2018) 18:7531.
  3. Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, Fowers K, Lewandowski R, Padia SA. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable Hepatocellular Carcinoma: The LEGACY Study. Hepatology. 2021 Mar 19. doi: 10.1002/hep.31819.
  4. Ranganathan S, Gabr A, Entezari P, Riaz A, Desai K, Thornburg B, Kulik L, Kalyan A, Salem R, Lewandowski RJ, Radioembolization for Intermediate Stage Hepatocellular Carcinoma Maintains Liver Function and Permits Systemic Therapy at Progression, Journal of Vascular and Interventional Radiology (2023).
  5. Atassi et al. Multimodality Imaging Following Y90 Radioembolization: A Comprehensive Review and Pictorial Essay. RadioGraphics, 2008.

TheraSphere is a registered trademark of Theragenics Corporation used under license by Boston Scientific Medical Device Limited, a wholly owned indirect subsidiary of Boston Scientific Corporation.